↓ Skip to main content

Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo

Overview of attention for article published in Journal of Translational Medicine, December 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
45 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo
Published in
Journal of Translational Medicine, December 2017
DOI 10.1186/s12967-017-1356-8
Pubmed ID
Authors

Ditte Reker, Cecilie F. Kjelgaard-Petersen, Anne Sofie Siebuhr, Martin Michaelis, Anne Gigout, Morten A. Karsdal, Christoph Ladel, Anne C. Bay-Jensen

Abstract

Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellular matrix (ECM) production. To gain further insight into the process of sprifermin in the cartilage tissue, this study aimed at investigating the ECM turnover of articular cartilage explants in a longitudinal manner. Bovine full-depth articular cartilage explants were stimulated with sprifermin or placebo at weekly intervals, similar to the dosing regimen used in clinical trials. Pre-culturing with oncostatin M and tumour necrosis factor-α, was also used to induce an inflammatory state before treatment. Metabolic activity was measured using AlamarBlue, and chondrocyte proliferation was visualized by immuno-histochemical detection of proliferating cell nuclear antigen. ECM turnover was quantified by biomarker ELISAs; ProC2 reflecting type II collagen formation, CS846 reflecting aggrecan formation, active MMP9, C2M and AGNx2 reflecting matrix metalloproteinase activity, and AGNx1 reflecting aggrecanase activity. Sprifermin was able to reach the chondrocytes through the extracellular matrix, as it increased cell proliferation and metabolic activity of explants. ProC2 and CS846 was dose-dependently increased (P < 0.05) by sprifermin compared to placebo, while C2M and AGNx2 were unaffected, active MMP9 was slightly decreased, and AGNx1 was slightly increased. Over the course of treatment, the temporal order of ECM turnover responses was AGNx1, then ProC2, followed by CS846 and MMP9. Pro-inflammatory activation of the explants diminished the ECM turnover responses otherwise observed under non-inflammatory conditions. The data suggest that sprifermin has chondrogenic effects on articular cartilage ex vivo, exerted through a sequential process of ECM turnover; aggrecan degradation seems to occur first, while type II collagen and aggrecan production increased at a later time point. In addition, it was observed that these chondrogenic effects are dependent on the inflammatory status of the cartilage prior to treatment.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 45 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 24%
Researcher 8 18%
Student > Master 7 16%
Student > Bachelor 3 7%
Student > Postgraduate 2 4%
Other 5 11%
Unknown 9 20%
Readers by discipline Count As %
Medicine and Dentistry 9 20%
Biochemistry, Genetics and Molecular Biology 7 16%
Pharmacology, Toxicology and Pharmaceutical Science 6 13%
Agricultural and Biological Sciences 5 11%
Immunology and Microbiology 1 2%
Other 3 7%
Unknown 14 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2018.
All research outputs
#3,779,403
of 13,205,256 outputs
Outputs from Journal of Translational Medicine
#604
of 2,611 outputs
Outputs of similar age
#128,633
of 384,927 outputs
Outputs of similar age from Journal of Translational Medicine
#53
of 262 outputs
Altmetric has tracked 13,205,256 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 2,611 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 384,927 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 262 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.